Core Viewpoint - Guangdong Naruida Radar Technology Co., Ltd. is making significant adjustments to its corporate governance and organizational structure to enhance operational efficiency and align with its strategic goals [3][6][38]. Group 1: Corporate Governance and Organizational Changes - The company has revised its Articles of Association to improve operational efficiency, with the changes pending approval from the shareholders' meeting [1][2]. - An organizational restructuring has been approved to optimize internal management and ensure stable business development [3][6]. Group 2: Fund Management and Financial Activities - The company plans to use up to RMB 300 million of idle raised funds to temporarily supplement its working capital, with a usage period not exceeding 12 months [6][10]. - The total amount raised from the initial public offering was approximately RMB 1.804 billion, with a net amount of RMB 1.654 billion after deducting issuance costs [6][8]. Group 3: Shareholder Meeting and Voting Procedures - The company will hold its first extraordinary general meeting of 2025 on June 16, 2025, with both onsite and online voting options available for shareholders [14][15]. - The meeting will address various proposals, including those related to asset restructuring and governance adjustments [18][20]. Group 4: Investment and Expansion Plans - The company is in the process of acquiring 100% equity of Tianjin Sigma Microelectronics Technology Co., Ltd. through a combination of share issuance and cash payment, along with raising matching funds [32][38]. - A wholly-owned subsidiary has been established in Hong Kong to enhance international presence and attract global talent, with a registered capital of HKD 10 million [46][48].

Core Viewpoint - The company plans to use bank acceptance bills and letters of credit to pay for part of the fundraising projects and will replace these payments with the raised funds, aiming to improve the efficiency of fund usage and reduce financial costs [1][7][9]. Fundraising Basic Situation - The company raised a total of RMB 75,438.20 million by issuing 51.67 million shares at RMB 14.60 per share, with actual funds received amounting to RMB 67,582.85 million after deducting issuance costs of RMB 7,855.35 million [1][2]. Fundraising Investment Project Situation - The company approved the use of RMB 57 million of excess funds to repay bank loans and made changes to the implementation of fundraising projects without altering the investment direction or total amount [2][3]. - The company has also approved the use of remaining funds from the "Kunshan Hanjing Precision Connector Production Project" for new projects, including "Semiconductor Metal Heat Sink Material Project" and "Automotive High-Frequency Signal Cable and Connector Project" [3][4]. Use of Bills and Letters of Credit - The company intends to use bank acceptance bills and letters of credit for payments, which will be replaced by the raised funds, following an internal approval process to ensure compliance and efficiency [6][7]. Impact on Daily Operations - The use of these financial instruments is expected to lower financial costs and enhance the flexibility of fund usage without affecting the normal progress of fundraising projects [7][9]. Approval Procedures and Opinions - The board and supervisory committee have reviewed and approved the use of bank acceptance bills and letters of credit, confirming that this does not change the direction of the raised funds and supports efficient fund usage [7][8].

Summary of Key Points Core Viewpoint - The company, Aibono Medical Technology Co., Ltd., is utilizing funds raised from a simplified issuance of shares to provide loans to its subsidiary, Tianyan Pharmaceutical, for the implementation of investment projects, ensuring compliance with regulatory requirements and maintaining the integrity of the fundraising purpose [1][4][5]. Fundraising Overview - The company plans to issue 3,593,615 shares at a price of 79.20 RMB per share, raising a total of 284,614,308 RMB, which will be used for specific investment projects [1][2]. - The total investment amount for the projects is 422,430,700 RMB, with 284,614,308 RMB allocated from the raised funds [2]. Investment Project Details - The funds will be allocated to various projects, with a total planned investment of 422,430,700 RMB, and the intended use of raised funds amounting to 284,614,308 RMB [2]. - The company may adjust the investment sequence and amounts based on project progress and funding needs, with any shortfall covered by self-raised funds [2]. Loan Provision to Subsidiary - The company intends to provide a loan of up to 260,000,000 RMB to Tianyan Pharmaceutical for the construction of an "invisible lens and injection mold processing production line" [3][4]. - The loan will be disbursed in batches based on project progress and actual funding needs, with interest rates determined by the latest published LPR [3][4]. Subsidiary Information - Tianyan Pharmaceutical, established on September 23, 2015, has a registered capital of 37,500,000 RMB and operates in pharmaceutical technology research and medical device production [3]. - As of December 31, 2024, Tianyan Pharmaceutical reported total assets of 541,571,200 RMB, total liabilities of 461,288,700 RMB, and a net profit of 7,607,000 RMB [3]. Purpose and Impact of the Loan - The loan aims to support the implementation of investment projects, aligning with the company's strategic planning and long-term interests without altering the intended use of raised funds [4][5]. - The management of the funds will adhere to strict regulatory protocols, ensuring effective oversight and compliance with relevant laws [4][5]. Review Procedures and Opinions - The board of directors and the supervisory board have approved the loan provision, confirming that it meets legal and regulatory standards and aligns with the company's long-term development needs [5][6].

二、募集资金投资项目情况 公司首次公开发行股票募集资金净额为人民币 122,466.93 万元，计划募集资 金金额为人民币 120,000 万元，超额募集资金金额为人民币 2,466.93 万元。公司 首次公开发行股票募集资金投资项目如下： | 序号 项目名称 | 总投资额 | | 募集资金投入金额 | | | --- | --- | --- | --- | --- | | （万元） （万元） | | | | | | 合计 120,000.00 120,000.00 | | | | | | 十八次会议以及 2021 年 12 月 16 日召开的 2021 年第三次临时股东大会审议通过 | | | | | | 了《关于使用部分超募资金用于永久补充流动资金的议案》，同意公司使用超募 | | | | | | 740 29.9968%，用于 资金中的 万元用于永久补充流动资金，占超募资金总额的 | | | | | | 公司与主营业务相关的生产经营活动。具体内容详见 2021 年 12 月 1 | | 日披露于上 | | | | 海证券交易所网站（www.sse.com.cn）的《北京亿华通科技股份有限公司关于使 | ...

证券代码：688339 证券简称：亿华通 公告编号：2025-031 北京亿华通科技股份有限公司 关于使用部分超募资金归还银行贷款的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京亿华通科技股份有限公司（以下简称公司）于 2025 年 5 月 29 日召开 第三届董事会第二十四次会议、第三届监事会第十九次会议审议通过了《关于 使用部分超募资金归还银行贷款的议案》，同意公司使用超募资金中的 740 万元 归还银行贷款，占超募资金总额的 29.9968%。本事项尚需提交公司股东大会审 议。 一、 募集资金基本情况 根据中国证券监督管理委员会《关于同意北京亿华通科技股份有限公司首 次公开发行股票注册的批复》（证监许可〔2020〕1447 号），公司获准向社会公 众公开发行人民币普通股 17,630,523 股，每股面值为人民币 1 元，每股发行价 格为人民币 76.65 元，募集资金总额为人民币 135,137.96 万元，扣除发行费用 后募集资金净额为人民币 122,466.93 万元。前述募集资金到位情况已经信永中 ...

证券代码：688050 证券简称：爱博医疗 公告编号：2025-034 爱博诺德（北京）医疗科技股份有限公司 关于使用募集资金向控股子公司提供借款以实施募投 项目的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 爱博诺德（北京）医疗科技股份有限公司（以下简称"公司"）于 2025 年 5 月 29 日召开第二届董事会第十九次会议和第二届监事会第十六次会议，审议通过 《关于公司使用募集资金向控股子公司提供借款以实施募投项目的议案》，同意 公司使用募集资金向控股子公司江苏天眼医药科技股份有限公司（以下简称"天 眼医药"）提供不超过 26,000.00 万元的借款以实施募投项目。公司监事会对本事 项发表了明确的同意意见，保荐机构中国银河证券股份有限公司（以下简称"保 荐机构"）对本事项出具了明确的核查意见。具体情况如下： 一、募集资金基本情况 根据中国证券监督管理委员会出具的《关于同意爱博诺德（北京）医疗科技 股份有限公司向特定对象发行股票注册的批复》（证监许可〔2025〕774 号）， 公司 2024 年度以简易程序向特 ...

证券代码：688050 证券简称：爱博医疗 公告编号：2025-029 爱博诺德（北京）医疗科技股份有限公司 第二届监事会第十六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 爱博诺德（北京）医疗科技股份有限公司（以下简称"公司"）第二届监事 会第十六次会议通知及相关材料于 2025 年 5 月 23 日以电子邮件的方式发出。会 议于 2025 年 5 月 29 日在公司会议室以现场与通讯相结合方式召开，本次会议由 监事会主席王丹璇女士召集并主持，应出席的监事 3 人，实际出席的监事 3 人。 本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法律、法规、 规章、规范性文件和《公司章程》等有关规定，会议形成的决议合法、有效。经 与会监事认真讨论，审议通过如下事项： 一、审议并通过《关于 2024 年年度利润分配方案的议案》 经与会监事认真审议，监事会认为：公司 2024 年年度利润分配方案充分考虑 了公司盈利情况、现金流状态及资金需求计划，结合了当前发展阶段、长远发展 规则及股东合理回报规划等各种 ...

Core Viewpoint - The company has approved the use of part of its raised funds, amounting to 50 million RMB, to provide a loan to its subsidiary, Hunan Hongrun Chemical Technology Co., Ltd., for the implementation of a project to produce 8,000 tons/year of photoinitiator H4 ketone [1][5]. Fundraising Overview - The company raised a total of 1,854.1574 million RMB through its initial public offering, with a net amount of 1,840.6713 million RMB after deducting issuance costs [1]. - The funds will be allocated to various projects, including the Hunan Hongrun project, which is part of a total investment plan of 2,155.5025 million RMB [2]. Loan Details - The loan to Hunan Hongrun will be provided in installments based on the project's construction schedule and actual funding needs, with a maximum term of 36 months [3][4]. - The interest rate for the loan will be determined based on the latest Loan Prime Rate (LPR) and the company's actual debt financing costs [3][4]. Purpose and Impact of the Loan - The loan aims to ensure the smooth implementation of the fundraising investment project and aligns with the planned use of raised funds, without altering the intended use or harming shareholder interests [5]. - Hunan Hongrun is a stable subsidiary with controllable financial risks, which supports the rationale for the loan [5]. Fund Management Post-Loan - The funds will be managed through a dedicated account at Hunan Hongrun, with a tripartite supervision agreement involving the company, a commercial bank, and the sponsor institution [6]. - The management of the funds will comply with relevant regulations and the company's fundraising management system [6]. Opinions from Supervisory Bodies - The supervisory board agrees that the loan aligns with the needs of the fundraising investment project and does not change the intended use of the funds, thus protecting the interests of the company and its shareholders [6]. - The sponsor institution has no objections to the loan arrangement, confirming compliance with regulatory requirements [6].

Group 1 - The core point of the announcement is the approval of the use of part of the raised funds to provide a loan to the subsidiary for the implementation of a fundraising project [1][2] - The Supervisory Board meeting was held on May 27, 2025, with all three supervisors present, and the resolutions passed were deemed legal and effective [1] - The loan amount approved is RMB 50 million, with an interest rate aligned with the current bank loan rate, aimed at supporting the "Ultra-High Precision Drive and Control Integration R&D Project" [1][2] Group 2 - The decision to provide the loan is in accordance with the fundraising plan and does not harm the interests of the company or its shareholders, particularly minority shareholders [1] - The resolution complies with relevant regulations, including the "Regulatory Guidelines for the Management and Use of Raised Funds by Listed Companies" and the "Shanghai Stock Exchange Science and Technology Innovation Board Listing Rules" [1]

Group 1 - The stock price of Daqo Energy (688303.SH) has declined to 19.27 yuan, representing a drop of 1.98%, and is currently in a state of below the issue price [1] - Daqo Energy was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on July 22, 2021, with an initial public offering (IPO) price of 21.49 yuan per share, raising a total of 644.7 million yuan [1] - The company planned to use the raised funds for projects including the annual production of 1,000 tons of high-purity semiconductor materials and 35,000 tons of polysilicon, as well as for working capital [1] Group 2 - In 2022, Daqo Energy issued A-shares to specific investors, raising approximately 10.99 billion yuan at an issue price of 51.79 yuan per share [2] - The net proceeds from this issuance, after deducting issuance costs, amounted to about 10.94 billion yuan, which has been fully utilized by the end of 2023 [2] - The total amount raised by Daqo Energy from both fundraising activities is approximately 17.447 billion yuan [3]